Health Policy Resources
The Axonics® SNM Systems are FDA-approved for the treatment of urinary and bowel dysfunction. Axonics provides the choice between rechargeable and recharge-free SNM therapies. Both Axonics SNM Systems deliver a long-lasting battery life for patients and reduces the need for device replacement surgeries.
Clinical Outcomes
Axonics Therapy has been the subject of 2 prospective, multicenter clinical studies. These studies have shown significant, durable symptom reductions and high rates of patient satisfaction with Axonics SNM Therapy.
Reimbursement
A quick-reference guide is available below for a summary of applicable codes and Medicare National Average payment rates for the procedures and sites of services typically associated with Sacral Neuromodulation therapy and Urethral Bulking
Healthcare Cost Savings
The Axonics SNM Systems may reduce patients’ and overall healthcare provider burden and risks associated with repeat surgeries.
A cost-consequence model was developed by health economic and physician experts to estimate the costs of long-term SNM-treatment with a rechargeable vs nonrechargeable device. The analysis determined that rechargeable SNM technology may deliver significant cost savings to payers, including
- 45% reduction in per patient costs
- $34,000 per patient savings
- $12 billion budget impact savings to US payers over 15 years.1
Health Economic Impact Reference
GO TO ARTICLEAdditional Resources
FDA Approval Letter Fecal Incontinence
GO TO ARTICLEFDA Approval Letter Urinary Incontinence
GO TO ARTICLEIf you have any further questions or inquiries, you may contact our Health Policy support
team at
This email address is being protected from spambots. You need JavaScript enabled to view it.
Axonics, Inc., does not guarantee that Medicare or any public or private payer will cover any
products or services at any particular level and specifically excludes any representation or warranty relating
to reimbursement. Laws, regulations, and payer policies concerning reimbursement are complex and change
frequently, and service providers are responsible for all decisions relating to coding and reimbursement
submissions. Accordingly, Axonics, Inc., strongly recommends that you consult with your payers, reimbursement
specialist and/or legal counsel regarding coding, coverage and payment matters.
References:
1. Noblett KL, Dmonchowski RR, Vasavada SP, et al. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder sysndrome. Neurourol Urodynam. 2016;1-7.
Questions?
We are here to help answer any questions you may have about Axonics Therapy.
